Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Viatris Inc.

Clinicaltrial registered6 Nov 2026

Viatris Inc.

6 Nov 2026: Trial registered · A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic Keratopathy. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
6 Nov 2026
Title
A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic Keratopathy
Conditions
Neurotrophic Keratopathy
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Recruiting
Countries
United States
Country
United States
Reference
NCT07923045
Location
United States
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Viatris Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Viatris Inc. in our registers.

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.